Cardicomm Solutions, Inc. Press Releases
TSX VENTURE SYMBOL: EKG
CARDIOCOMM SOLUTIONS FILES WITH HEALTH CANADA FOR DIRECT TO CONSUMER SALES APPROVAL OF THE HEARTCHECK™ CARDIBEAT HANDHELD ECG DEVICE
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, has filed with Health Canada for approval for the over-the-counter (“OTC”) sales and marketing of their GEMS™ Mobile smartphone app and their newest handheld, heart rhythm monitor, the HeartCheck™ CardiBeat. Both were...
CARDIOCOMM SOLUTIONS TO ISSUE SHARES UNDER ONLINE MARKETING AND AWARENESS PROGRAM
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, announced that it will make its second issuance of shares under its online marketing and awareness program with AGORA Internet Relations Corp. (“AGORACOM”). The Company previously announced the online marketing and awareness program...
CARDIOCOMM SOLUTIONS LAUNCHES NEW GEMS™ MOBILE UNIVERSAL ECG APP EXPANDING ECG REPORTING SERVICES ACROSS GLOBAL MARKETS
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, announces the release of a new version of the Company’s recently cleared US Food and Drug Administration (“FDA”) GEMS™ Mobile ECG app. The new version is branded as the GEMS™ Universal ECG (“GEMS™...
CARDIOCOMM SOLUTIONS LEVERAGES THE GEMSTM MOBILE ECG APP TO BRING A THIRD FDA CLEARED HEARTCHECK™ BRANDED ECG DEVICE TO THE US CONSUMER MARKETS
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, confirms the start of an OEM co-marketing agreement for the HeartCheck™ Palm handheld ECG device, the Company’s newest GEMS™ Mobile ECG app ("GEMSTM Mobile") enabled ECG device. The HeartCheck™ Palm will be the Company's...
CARDIOCOMM SOLUTIONS RELEASES REMOTE 12-LEAD ECG TELEMED SOLUTION WITH ARRYTHMIA DETECTION AND ECG READING SERVICES
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, has released GlobalCardio 12 FLEX ("GC12 FLEX"), a complete remote 12-lead ECG acquisition and reading solution. GC12 FLEX has been developed for use by clinics and telemedicine groups that operate from multiple locations and that require rapid...
CARDIOCOMM SOLUTIONS PREPARES NEW FDA APPLICATIONS FOR DIRECT-TO-CONSUMER AND PHYSICIAN USE CARDIAC ARRHYTHMIA ALGORHYTHMS
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, is preparing US Food and Drug Administration ("FDA") 510(k) Class II medical device clearance applications for new arrhythmia detection algorithms. The main application will be for GEMS™ Rhythm, a full suite of arrhythmia detection tools...
INNOVATION CONTINUES AS THE FDA CLEARS CARDIOCOMM SOLUTIONS’ NOVEL ECG SMARTPHONE APP AND HEARTCHECK™ DEVICE FOR DIRECT TO CONSUMER SALES
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, has received approval from the US Food and Drug Administration (“FDA”) for the over-the-counter ("OTC") sales and marketing of their device agnostic GEMS™ Mobile smartphone app and their newest handheld, heart rhythm monitor,...
CARDIOCOMM SOLUTIONS ENGAGES US LAW FIRM TO ADDRESS LICENSING AND IP OPPORTUNITIES
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, confirms it has retained Whiteford, Taylor & Preston L.L.P. to assist in software licensing and intellectual property business matters on a go forward basis. Whiteford, Taylor & Preston includes over 170 attorneys in sixteen offices located in...
CARDIOCOMM SOLUTIONS NOW OFFERS A SMARTPHONE CONNECTED FDA CLEARED 12 LEAD ECG BELT UNDER A NEW CO-MARKETING AGREEMENT
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, confirms it has entered into a device technology relationship for the co-marketing and US sales of a Smartphone connected 12 lead ECG wearable device. The announcement follows the successful integration and testing of the device with...
CARDIOCOMM SOLUTIONS’ HEARTCHECK™ DEVICE ENTERS FINAL FDA REVIEW PHASE
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, confirms it has completed a request for additional information from the US Food and Drug Administration (“FDA”) for the Company’s premarket notification 510(k), Class II medical device clearance application for the...
CARDIOCOMM SOLUTIONS COMPLETES WORK ON ARRHYTHMIA DETECTION ALGORITHMS WITH ARTIFICIAL INTELLIGENCE-BASED LEARNING
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, confirms completion of a six month collaborative project with researchers at the University of Victoria, Canada, leading the way to a release of artificial intelligence ("AI") enhancements to CardioComm's Global ECG Management Solution ("GEMS™")...
CARDIOCOMM SOLUTIONS’ HEARTCHECK™ CARDIBEAT FDA 510(K) REVIEW EXTENDED
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") acquisition and management software solutions, confirms the USA Food and Drug Administration ("FDA") has reduced the scope of their request for additional information for the Company's premarket notification 510(k), Class II medical device clearance application for the HeartCheck™...
CARDIOCOMM SOLUTIONS PROVIDES FINANCING UPDATE
--> TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, confirms the renewal of $600,000 in loans that would have matured December 31, 2018. The maturing loans were made to the Company in December 2016 as described in the Company's press release dated December 21, 2016. The four lenders that participated in the 2016...
CREO WELLNESS SELECTS CARDIOCOMM SOLUTIONS’ ECG MONITORING SERVICE FOR INTEGRATION WITH USA PATIENT ENGAGEMENT PLATFORM
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company" or "CCS"), a global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, and Virginia-based connected health provider Creo Wellness, LLC (“CREO”) confirm the companies have committed to integrate CardioComm’s ECG monitoring service technologies and ECG devices to support the CREO physician...
CARDIOCOMM SOLUTIONS TO ISSUE SHARES UNDER ONLINE MARKETING AND AWARENESS PROGRAM
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announced that it will makes its first issuance of shares under its online marketing and awareness program with AGORA Internet Relations Corp. ("AGORACOM"). The Company initially announced the online marketing and awareness program in its press release dated November 8,...
CARDIOCOMM SOLUTIONS SECURES MDSAP ISO CERTIFICATION FOR THE MANUFACTURING, MARKETING AND SALE OF CONSUMER AND Rx MEDICAL DEVICES INTO THE USA AND CANADA
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, has completed its ISO 13485:2016 ("ISO") certification in compliance with the Medical Device Single Audit Program ("MDSAP"), which is now mandatory under Health Canada requirements and recommended by the USA Food and Drug Administration ("FDA")....
CARDIOCOMM SOLUTIONS APPOINTS NEW CHIEF FINANCIAL OFFICER
TORONTO, ONTARIO - Established medial electrocardiogram ("ECG") software and device manufacturer CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company") today confirmed the appointment of a new Chief Financial Officer ("CFO"), Ms. Anne Burpee. Ms. Burpee is a bilingual Chartered Professional Accountant with more than 25 years of senior finance and executive experience in both large and small companies. She has held several corporate positions in...
CARDIOCOMM SOLUTIONS’ HEARTCHECK™ CARDIBEAT AND SMART PHONE APP ENTER FINAL STAGE OF FDA 510(K) REVIEW
TORONTO, ONTARIO - CardioComm Solutions, Inc. ("CardioComm" or the "Company") (TSX VENTURE:EKG) a global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, has completed its response to the USA Food and Drug Administration ("FDA") for additional information following the Company's filing of its premarket notification 510(k), Class II medical device clearance application for the HeartCheck™ CardiBeat...
CARDIOCOMM SOLUTIONS LAUNCHES ONLINE MARKETING AND AWARENESS PROGRAM
TORONTO, ONTARIO - CardioComm Solutions, Inc. ("CardioComm" or the "Company") (TSX VENTURE:EKG) a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce that it is implementing an online marketing and awareness program through AGORA Internet Relations Corp. ("AGORACOM"). AGORACOM's program will provide the Company a significant level of exposure through millions of content brand insertions on the...
CARDIOCOMM SOLUTIONS LAUNCHES 12-LEAD ECG SMART WEARABLE GARMENT MONITORING SOLUTION
TORONTO, ONTARIO - CardioComm Solutions, Inc. ("CardioComm" or the "Company") (TSX VENTURE:EKG) a global medical provider of consumer heart monitoring and medical electrocardiogram (“ECG”) software solutions, today announced its joint partnership sales plans for the commercial launch of its newest software release designed to support an innovative and easy to use wireless, 12 lead ECG, vital signs, arrhythmia and ischemia monitoring wearable smart garment...
CARDIOCOMM SOLUTIONS TO RECEIVE ROYALTY PAYMENTS FROM BIOTRICITY
TORONTO, ONTARIO - CardioComm Solutions, Inc. ("CardioComm" or the "Company") (TSX VENTURE:EKG) a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions confirmed today progress on a royalty licencing agreement with Redwood City, California-based Biotricty Inc. ("Biotricity"). The royalty payment phase became active following confirmation that all necessary clearance and software development pre-conditions...
CARDIOCOMM SOLUTIONS SETS THE RECORD STRAIGHT; THE FIRST COMPANY TO RECEIVE APPROVAL FOR ECG PRODUCT SALES DIRECT TO CONSUMERS
TORONTO, ONTARIO - CardioComm Solutions, Inc. ("CardioComm" or the "Company") (TSX VENTURE:EKG) a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, firmly responds to recent technology companies' announcements that it was the first company to be approved to sell an ECG product directly to consumers over the counter ("OTC") in North America. CardioComm was the first company to be approved to sell an...
CARDIOCOMM SOLUTIONS ANNOUNCES EXTENSION OF WARRANTS
--> TORONTO, ONTARIO - CardioComm Solutions, Inc. ("CardioComm" or the "Company") (TSX VENTURE:EKG) a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, announced that it is seeking approval from the TSX Venture Exchange to extend the expiry dates of outstanding warrants exercisable to purchase an aggregate of 8,346,000 common shares of the Company at $0.075 per share. 7,300,000 of the warrants were...
CARDIOCOMM SOLUTIONS COMPLETES HEARTCHECK™ CLINICAL VALIDATION FOR LONG-TERM, SELF-MANAGED, REMOTE MONITORING OF ATRIAL FIBRILLATION PATIENTS POST-ABLATION
TORONTO, ONTARIO - CardioComm Solutions, Inc. ("CardioComm" or the "Company") (TSX VENTURE:EKG) a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, confirms its HeartCheck™ device and GEMS™ software technologies have moved into routine clinical use following completion of a long-term, remote arrhythmia monitoring pilot in high risk patients. Partners in Advanced Cardiac Evaluation...
CARDIOCOMM SOLUTIONS FDA 510K APPLICATION FOR NEWEST HEARTCHECK™ ECG DEVICE AND SMART PHONE APP ENTERS THE NEXT STAGE OF REVIEW
TORONTO, ONTARIO - CardioComm Solutions, Inc. ("CardioComm" or the "Company") (TSX VENTURE:EKG) a leading global provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, has received a request for additional information from the USA Food and Drug Administration ("FDA") following the Company's filing of its premarket notification 510(k), Class II medical device clearance application for the HeartCheck™ CardiBeat and...
CARDIOCOMM SOLUTIONS ISSUES STOCK OPTIONS
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, announces that it has issued 62,500 stock options to Etienne Grima, the Company’s CEO, in accordance with his employment agreement. The options are exercisable at $0.05 per Share for five years from the date of grant and vest immediately....
